Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 9/20 | 0.71 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | GALR3 | O60755 | 1/20 | 0.71 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.71 |
| ▸ | DPP4 | P27487 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | GAPDH | P04406 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419177 | 1.00 | ADK (0.71) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL22399485 | 1.00 | ADK (0.71) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL19402572 | 1.00 | ADK (0.71) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL20419133 | 1.00 | ADK (0.71) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL20419130 | 1.00 | ADK (0.71) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL22381626 | 1.00 | ADK (0.71) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL24837542 | 0.91 | ADK (0.60) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL19402610 | 0.91 | ADK (0.60) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL31725292 | 0.91 | ADK (0.59) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL15948775 | 0.91 | PRMT5 (0.60) | ADKDOT1LNPC1GALR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334745-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3334745-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2005016878-A2 | METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADK 471/4885DOT1L 4213/4885NPC1 3174/4885 |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADK 471/4885DOT1L 4213/4885NPC1 3174/4885 |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADK 471/4885DOT1L 4213/4885NPC1 3174/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADK 471/4885DOT1L 4213/4885NPC1 3174/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ADK 471/4885DOT1L 4213/4885NPC1 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.